Institut Curie
3 clinical trials · 3 recruiting · OTHER
Trials by Institut Curie
RECRUITINGPhase 2NCT07193394
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
The H3RAKLES trial would allow patients with a progressive metastatic breast cancer to have access to one more line of systemic therapy. Patients included in this trial will have...
Sponsor: Institut CurieEnrolling: 209 locations
Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer
RECRUITINGPhase 3NCT05439005
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III...
This study will compare morphine consumption during the first 48 hours postoperatively between the OFA group and the CA control group.
Sponsor: Institut CurieEnrolling: 1583 locations
Breast Cancer
RECRUITINGNCT05475366
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of...
Sponsor: Institut CurieEnrolling: 857 locations
Carcinoma, Pancreatic DuctalPrognosis